Literature DB >> 17226008

[Therapy with entecavir in chronic hepatitis B. BEHoLD-Study (Benefits of Entecavir for Hepatitis B Liver Disease)].

S Nitschman, A Erhardt, A Häussinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17226008     DOI： 10.1007/s00108-006-1787-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  1 in total

1.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.